This presentation will cover:

• Predicting patient response to immunotherapies requires a robust and comprehensive approach to tumor immunogenomics.
• By combining highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics, ImmunoID NeXT™ provides a broad view of the tumor and the immune-related components of the tumor microenvironment from a single, limited sample.
• Combination of ImmunoID NeXT and our exome-wide liquid biopsy assay, NeXT Liquid Biopsy, allows for increased exploration of critical areas of tumor biology.